You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience

Article metrics

Article menu
Clinical/translational cancer immunotherapy
CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience

 

Online download statistics by month:

Online download statistics by month: February 2022 to January 2026

AbstractFullPdf
Feb 2022620641290
Mar 2022283293142
Apr 202227027779
May 202218418952
Jun 202229930873
Jul 202231531939
Aug 202231632658
Sep 202233533991
Oct 202231632165
Nov 202228028035
Dec 202226226231
Jan 202326927127
Feb 202325025136
Mar 202326126249
Apr 202319319336
May 202321221228
Jun 202321321431
Jul 202321821828
Aug 202320220227
Sep 202318518517
Oct 202320220221
Nov 202320420418
Dec 202321121245
Jan 20249910133
Feb 202414914933
Mar 2024209209150
Apr 202419119239
May 202421822130
Jun 202418218221
Jul 202419719835
Aug 2024183182204
Sep 2024909233
Oct 202415515627
Nov 202422222338
Dec 202422923227
Jan 202520320438
Feb 202520320427
Mar 202516716728
Apr 202517918230
May 202519819940
Jun 202516616835
Jul 2025110
Aug 2025110
Sep 2025110
Dec 2025550
Jan 2026001
Total934894502187